BEACON PHARMACEUTICALS LIMITED

Active Ashford

Manufacture of pharmaceutical preparations

0 employees website.com
Manufacture of pharmaceutical preparations
B

BEACON PHARMACEUTICALS LIMITED

Manufacture of pharmaceutical preparations

Founded 21 Mar 2000 Active Ashford, England 0 employees website.com
Manufacture of pharmaceutical preparations
Accounts Submitted 26 Jan 2026 Next due 31 Dec 2026 6 months remaining
Confirmation Submitted 23 Mar 2026 Next due 4 Apr 2027 10 months remaining
Net assets £1M £1K 2024 year on year
Total assets £1M £0 2024 year on year
Total Liabilities £2K £1K 2024 year on year
Charges 2
2 outstanding

Contact & Details

Contact

Registered Address

2nd Floor, Connect 38 1 Dover Place Ashford Kent TN23 1FB England

Full company profile for BEACON PHARMACEUTICALS LIMITED (03953215), an active company based in Ashford, England. Incorporated 21 Mar 2000. Manufacture of pharmaceutical preparations. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Apr → 31 Mar 2025
Type audit-exemption-subsidiary
Next accounts 31 Mar 2026
Due by 31 Dec 2026 6 months remaining

Balance Sheet & P&L (2014–2024)

Cash in Bank

N/A

Net Assets

£1.24M

Decreased by £1.00k (-0%)

Total Liabilities

£2.00k

Increased by £1.00k (+100%)

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Mar Year End
2024
31 Mar Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

1 active 2 resigned
Status
James, KevinDirectorBritishEngland7123 Mar 2022Active

Shareholders

Shareholders (1)

Kent Pharmaceuticals Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 21 Jun 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,right To Appoint And Remove Directors,significant Influence Or Control As Firm

Group Structure

Group Structure

BEACON PHARMACEUTICALS LIMITED Current Company

Charges

Charges

2 outstanding

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
23 Mar 2026Confirmation StatementConfirmation statement made on 21 Mar 2026 with no updates
26 Jan 2026OtherAudit exemption statement of guarantee by parent company for period ending 31/03/25
26 Jan 2026AccountsAnnual accounts made up to 31 Mar 2025
8 Jan 2026OtherNotice of agreement to exemption from audit of accounts for period ending 31/03/25
8 Jan 2026AccountsAnnual accounts filed
23 Mar 2026 Confirmation Statement

Confirmation statement made on 21 Mar 2026 with no updates

26 Jan 2026 Other

Audit exemption statement of guarantee by parent company for period ending 31/03/25

26 Jan 2026 Accounts

Annual accounts made up to 31 Mar 2025

8 Jan 2026 Other

Notice of agreement to exemption from audit of accounts for period ending 31/03/25

8 Jan 2026 Accounts

Annual accounts filed

Recent Activity

Latest Activity

Confirmation statement made on 21 Mar 2026 with no updates

2 months ago on 23 Mar 2026

Audit exemption statement of guarantee by parent company for period ending 31/03/25

4 months ago on 26 Jan 2026

Annual accounts made up to 31 Mar 2025

4 months ago on 26 Jan 2026

Notice of agreement to exemption from audit of accounts for period ending 31/03/25

5 months ago on 8 Jan 2026

Annual accounts filed

5 months ago on 8 Jan 2026